MediciNova (MNOV) Expected to Announce Quarterly Earnings on Wednesday

MediciNova (NASDAQ:MNOV - Get Free Report) is expected to be announcing its results after the market closes on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $0.1280 million for the quarter.

MediciNova (NASDAQ:MNOV - Get Free Report) last released its earnings results on Friday, February 20th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.05. The firm had revenue of $0.15 million for the quarter. On average, analysts expect MediciNova to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MediciNova Trading Up 0.7%

NASDAQ MNOV opened at $1.41 on Wednesday. MediciNova has a 12 month low of $1.17 and a 12 month high of $1.96. The stock has a market cap of $69.40 million, a price-to-earnings ratio of -5.87 and a beta of 0.63. The company's 50 day moving average is $1.42 and its two-hundred day moving average is $1.46.

Institutional Investors Weigh In On MediciNova

Institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC purchased a new stake in MediciNova during the 4th quarter valued at approximately $214,000. Citadel Advisors LLC purchased a new position in shares of MediciNova in the third quarter valued at $92,000. State Street Corp grew its holdings in shares of MediciNova by 10.9% in the fourth quarter. State Street Corp now owns 193,698 shares of the biopharmaceutical company's stock valued at $254,000 after purchasing an additional 19,100 shares in the last quarter. Goldman Sachs Group Inc. purchased a new position in shares of MediciNova in the fourth quarter valued at $35,000. Finally, StoneX Group Inc. purchased a new position in shares of MediciNova in the fourth quarter valued at $25,000. 9.90% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on MNOV shares. Maxim Group restated a "buy" rating and set a $6.00 target price on shares of MediciNova in a research note on Monday, March 23rd. Weiss Ratings restated a "sell (d-)" rating on shares of MediciNova in a research note on Friday, March 27th. Zacks Research upgraded shares of MediciNova to a "hold" rating in a research note on Tuesday, March 17th. HC Wainwright assumed coverage on shares of MediciNova in a research note on Monday, March 16th. They set a "buy" rating and a $10.00 target price on the stock. Finally, D. Boral Capital reaffirmed a "buy" rating and set a $9.00 price objective on shares of MediciNova in a report on Monday. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $7.50.

About MediciNova

MediciNova, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule therapeutics for neurodegenerative, inflammatory, fibrotic and oncological diseases. Founded in the late 1990s, the company advances its proprietary compounds through clinical trials and strategic partnerships, with a goal of addressing areas of high unmet medical need. MediciNova is headquartered in San Diego, California, and maintains a presence in Tokyo to support collaborations and regulatory interactions in Asian markets.

The company's leading clinical asset, MN-166 (ibudilast), is an anti-inflammatory and neuroprotective agent originally approved in Japan for asthma and post-stroke dizziness.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.